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Scan the quick response (QR) code to the left with your mobile device to watch this article's video abstract and others. Don't have a QR code reader? Get one by searching 'QR Scanner' in your mobile device's app store. P ortal vein thrombosis (PVT) is a critical but frequent event in patients with cirrhosis. Its reported incidence in compensated disease ranges from 0.6% to 5%, which increases up to 40% in advanced disease. [1] [2] [3] PVT may result in deterioration of the clinical course, 4 increased complications caused by portal hypertension (PH), 5 and post-transplant mortality. 6, 7 Its development is associated inversely with platelet levels. 1, 8 Other risk factors for PVT include recurrent liver decompensation 3 and history of infection, 9 bleeding, endoscopic treatment, and abdominal surgery (eg, splenectomy, and so forth). 10 The local and systemic factors involved in PVT pathogenesis suggest a procoagulant, multifactorial status culminating in PVT in cirrhotic patients. Local alterations may include changes in the liver cytoarchitecture, including periportal lymphangitis and fibrosis, 11, 12 leading to flow reduction and endothelial activation. 13 Systemic factors include altered levels of natural inhibitors of coagulation, 14 inherited coagulation abnormalities, 15 and the presence of antiphospholipid antibodies. 16 Because anticoagulants can reverse acute PVT in subjects without liver disease, 17 the efficacy of anticoagulation in treating PVT has been tested in cirrhotic patients. Francoz et al 8 showed that sequential anticoagulation with low-molecularweight heparin and vitamin K antagonists resulted in a 42% complete recanalization (in the period between enrollment and transplant), without bleeding complications. However, no randomized prospective studies devoted to PVT prevention have been performed. We designed a pragmatic, nonprofit, randomized, controlled trial (RCT) comparing the safety and efficacy of enoxaparin with no treatment in patients with advanced cirrhosis, with the primary end point of preventing PVT. Secondary end points were prevention of liver decompensation, overall survival, and transplant-free survival. Because a compromised intestinal mucosal barrier (as found in advanced cirrhosis) 18, 19 may lead to increased bacterial translocation and favor inappropriate activation of coagulation, we also evaluated intestinal fatty acid binding protein (I-FABP), a marker of enterocyte damage and 3 markers associated with microbial translocation and the immune response to it (16S ribosomal DNA [rDNA], soluble CD14 [sCD14], interleukin [IL]-6) 20 to evaluate whether enoxaparin, by improving intestinal microcirculation, was able to decrease mucosal ischemia and reduce bacterial translocation.
Materials and Methods

Study Design and Participants
Between April 2008 and November 2010, all consecutive patients seen at a tertiary referral liver unit (Azienda Ospedaliero-Universitaria, Modena) and satisfying predefined inclusion criteria were recruited. Eligible patients were 18 years and older and had cirrhosis of any etiology, a Child-Pugh score between B7 and C10, absence of ascites, spontaneous bacterial peritonitis (SBP), portal hypertensive bleeding or portosystemic encephalopathy for at least 3 months before enrollment, and no evidence of PVT or splenomesenteric thrombosis by ultrasound evaluation and angio-computed tomography. Before enrollment, all patients underwent hepatic, renal, and coagulative evaluations.
Exclusion criteria were as follows: age older than 75 years; history of gastrointestinal bleeding, hepatocellular carcinoma, other intrahepatic/extrahepatic cancers, or thromboembolic disease; ongoing anticoagulation, antiaggregation, or antiphospholipid antibody treatment; pregnancy or breastfeeding; F2 varices with red whale marks or F3 varices unless ligated; platelet count less than 10,000/mm 3 ; evidence of paroxysmal nocturnal hemoglobinuria (based on CD55-CD59 flow cytometry); or human immunodeficiency virus infection.
All patients provided written informed consent. The study protocol was approved by the Ethics Committee of Azienda Ospedaliero-Universitaria, Modena (ISRCTN32383354, EudraCT 2007-007890-22). The study was conducted according to the guidelines of the Declaration of Helsinki and the applicable provisions of Good Clinical Practice in clinical trials. All authors had access to the study data, reviewed, and approved the final manuscript.
Study Design
The experimental arm received enoxaparin (Clexane; Sanofi Aventis, Milan, Italy) subcutaneously at a prophylactic dose (4000 IU/day) for 48 weeks. The control arm received no treatment. After the first year, both groups continued follow-up evaluation.
Randomization and Masking
Patients were randomized to treatment groups by an independent statistician who prepared sequentially numbered, sealed, opaque envelopes derived from a computer-generated scheme, with a concealed block size of 10. Patients who met the inclusion criteria were assigned randomly, with equal probability, to 1 of 2 treatment arms. Caregivers and patients were not masked to treatment assignments. Radiologists and hepatologists (performing computed tomography and ultrasound, respectively) assessing primary outcome were instead blinded to group assignment.
Efficacy Assessment
The primary end point of the study was the 2-year prevention of portal or mesenteric vein thrombosis. Ultrasound evaluation of the portal vein system was performed at baseline and every 3 months thereafter. Patency of the portal vein system was confirmed at enrollment and at weeks 48, 96, and 144 by angio-computed tomography (which was repeated whenever a thrombotic event was suspected). Secondary end points were as follows: (1) occurrence or recurrence of liver decompensation, defined as development of ascites, portosystemic encephalopathy, SBP, or portal hypertensive bleeding; and (2) overall and transplant-free survival.
Patients were seen regularly in the outpatient clinic every 3 months, unless their clinical condition required more frequent monitoring. At each interval, complete biochemical tests were obtained. Patients who stopped the planned treatment or missed 2 consecutive drug doses at any time, because of subjective intolerance or side effects, would have been considered as withdrawn from treatment. All other patients were followed up until death, liver transplant, or completion of the study. Results were analyzed by intention to treat. Reporting of this RCT was performed according to criteria in the last CONSORT statement. 21 
Safety Assessment
Side effects were recorded according to the World Health Organization grading system of toxicity. 22 Protocol guidelines allowed for dose interruption in patients who had relevant adverse events or important laboratory value abnormalities. If these issues resolved, then the drug was restarted; otherwise, therapy was stopped.
3 hours, DNA was purified by the spin column method and eluted with 30 L of sterile water.
Microbial DNA amplification by polymerase chain reaction. A 24-L aliquot of the DNA template was added to polymerase chain reaction (PCR) mixtures that contained 50 pmol of each appropriate primer (oligonucleotide primers, forward: 5=-GATCATGGCT CAGATTGAAC G-3= and reverse: 5=-CGTAT-TACCG CGGCTGCT-3=) (Eurofins MWG Operon, Ebersberg, German), 200 mol/L of each deoxynucleoside triphosphate, 1ϫ Taq buffer advanced (5 PRIME, Gaithersburg, MD), 2.5 U of Taq DNA polymerase (5 PRIME), and 16 L of deionized water. The total reaction volume was 50 L.
The PCR primers were designed against a conserved region of the bacterial 16S ribosomal RNA gene with Primer3 software (available at: http://www.bioinformatics.nl/cgi-bin/primer3plus/ primer3plus.cgi) and the Escherichia coli 16S ribosomal RNA sequence (gene accession number: J01695). The expected amplicon size was approximately 521 bp. In each PCR assay, positive controls (DNA from E coli DH5␣) and negative controls (sterile water and PCR mixtures, without DNA) were used.
PCR was performed on a GeneAmp PCR System 2700 thermal cycler (Applied Biosystems, Carlsbad, CA). The PCR running conditions were an initial denaturation of 94°C for 6 minutes, followed by 35 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds, with a final extension step at 72°C for 10 minutes. Purified products were separated on 1.8% agarose gel containing ethidium bromide by electrophoresis. The PCR products were visualized by exposure to UV light on a Trans illuminator and photographed with a Molecular Imager Gel Doc XRϩ System (Bio-Rad, Hercules, CA). A band of approximately 521 bp was obtained, corresponding to the specific amplification of the prokaryotic 16S ribosomal RNA gene.
Bacterial DNA (16S rDNA) in sera was PCR-amplified at baseline and at 48 and 72 weeks from enrollment.
Determination of serum I-FABP, IL-6, sCD14. I-FABP, IL-6, and sCD14 levels were measured in duplicate with a commercial enzyme-linked immunosorbent assay kit, according to the manufacturer's instructions. Serum I-FABP concentrations were tested with the human I-FABP enzyme-linked immunosorbent assay kit (Hycult Biotechnology, PB Uden, The Netherlands), according to the manufacturer's instructions. Serum IL-6 and sCD14 levels were determined with the quantikine/high-sensitivity enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. Each experiment was performed in duplicate. Absorbances were measured at 450 and 490 nm with an automatic microplate reader (Multiskan EX; Thermo Fisher Scientific, Inc, Waltham, MA), with background subtraction at 570 and 650 nm, respectively.
Statistical Analysis
Prevention of 2-year portal or splenomesenteric vein thrombosis was chosen as the primary outcome to calculate sample size. Assuming a 20% difference in the 2-year rate of portal or splenomesenteric vein thrombosis between the enoxaparin (5%) and control groups (25%), and 5% ␣ error and 20% ␤ error, 34 patients were needed in each group.
Dichotomous or continuous variables were compared with the Fisher exact test with mid-p correction or the nonparametric MannWhitney rank-sum test, respectively. The Kaplan-Meier method was used to estimate the cumulative probability of portal or splenomesenteric vein thrombosis development, occurrence or recurrence of liver decompensation, and overall or transplant-free survival. Differences in observed probability were assessed by log-rank test.
The following variables at baseline were considered for univariate analysis: age, sex, etiology of cirrhosis (viral vs nonviral), Child-Pugh score, Model for End-Stage Liver Disease (MELD) score, esophageal varices size, portal vein diameter, allocation to treatment, platelet level, bilirubin level, albumin level, international normalized ratio (INR), creatinine level, sodium level, and potassium level. To avoid the effect of colinearity, individual components of the MELD score (bilirubin level, INR, and creatinine level) were not included in multivariate models that included the MELD score. Variables with a P value of less than .10 in univariate analysis were included in the final multivariate model. The Cox proportional hazards model was used to identify risk factors for portal or splenomesenteric vein thrombosis development, occurrence or recurrence of liver decompensation, and overall or transplant-free survival. The PASW Statistics 18 program (SPSS, Inc, Chicago, IL) was used for analysis.
Results
Supplementary Figure 1 shows the trial profile. A total of 396 patients with cirrhosis were screened for study eligibility: 326 patients were excluded (Supplementary Figure 1 ), and 70 patients were assigned randomly to the enoxaparin (n ϭ 34) or control group (n ϭ 36). All patients but 1 (withdrawn for thrombocytopenia) completed the treatment. The trial was completed as planned in November 2011. There were no missing values for the primary outcome. There were no significant differences in baseline characteristics between the 2 groups at the time of entry into the study ( Table 1 ). The mean (Ϯ standard deviation) follow-up period was 58 Ϯ 37 weeks in the control and 89 Ϯ 57 weeks in the enoxaparin group. Seven patients (4 controls, 3 enoxaparin patients) underwent liver transplantation during the follow-up period.
PVT Incidence
During the year of active treatment, no patient in the enoxaparin group (0 of 34) developed PVT, compared with 6 of 36 (16.6%) controls (P ϭ .025). At 2 years, none of the enoxaparin-treated patients (0 of 34) had yet developed PVT, compared with 10 of 36 (27.7%) controls (P ϭ .001). Enoxaparin-treated patients developed PVT only at weeks 105, 111, and 121 after enrollment. Overall, 3 of 34 (8.8%) enoxaparin-treated patients and 10 of 36 (27.7%) controls developed PVT (P ϭ .048). All patients developing PVT in the enoxaparin group and 9 of 10 patients developing PVT in the control group were symptomatic. The actuarial probability of developing PVT was lower in the enoxaparin-treated group (P ϭ .006) ( Figure 1A ). Cox regression analysis showed that enoxaparin treatment (hazard ratio [HR], 0.098; 95% CI, 0.014 -0.697; P ϭ .020) and higher protein C levels (HR, 0.984; 95% CI, 0.858 -0.981; P ϭ .012) were associated independently with a decreased risk of developing PVT (Supplementary Table 1 ).
Occurrence of Decompensation
During the active treatment period, decompensation was more frequent in controls than in enoxaparintreated patients ( .0001). During the follow-up period, new decompensation occurred in 9 of 31 (29.0%) controls and 9 of 32 (28.0%) enoxaparin-treated patients (P ϭ .890). Overall, decompensation occurred in 30 of 36 (83.0%) controls and 13 of 34 (38.2%) enoxaparin-treated patients (P Ͻ .0001). In the year of active treatment, occurrence of decompensation was significantly lower in enoxaparin-treated patients independently from previous decompensation (previous de- Paired comparison within enoxaparin-treated patients and control groups of markers of disease severity (albumin level, INR, bilirubin level) and of renal function (creatinine) between baseline and 48 weeks (before stopping treatment) or 96 weeks showed a significant improvement of all liver tests but renal function in enoxaparin-treated patients at 48 weeks. In contrast, in controls, paired comparison showed worsening of renal function both at 48 (P ϭ .021) and 96 weeks (P ϭ .030) whereas liver function tests showed a trend toward deterioration, although the trend was nonsignificant ( Table 2) .
The actuarial probability of developing decompensation was lower in enoxaparin-treated patients than in controls (P Ͻ .0001) ( Figure 1B) . Cox regression analysis showed that enoxaparin treatment (HR, 0.331; 95% CI, 0.148 -0.741; P ϭ .007), baseline bilirubin level (HR, 1.478; 95% CI, 1.074 -2.033; P ϭ .017), portal vein diameter (HR, 1.216; 95% CI, 1.010 -1.464; P ϭ .026), and previous encephalopathy (HR, 3.196; 95% CI, 1.282-7.964; P ϭ .013) were independent risk factors for decompensation (Supplementary Table 2 ). Actuarial probability during follow-up evaluation of not changing or worsening by 2 or more points in the Child-Pugh score was different between enoxaparin-treated and control patients (P Ͻ .0001) (Figure 2 ). The improvement of clinical conditions was paralleled by a significant difference both in the number of patients requiring hospital admission (enoxaparin-treated patients vs controls: 11 of 34 [32.3%] vs 22 of 36 [55.5%], respectively; P ϭ .016) and in the length of stay in hospital (enoxaparin-treated patients vs controls: 6.1 Ϯ 14.6 vs 15.2 Ϯ 17.6 days, respectively; P ϭ .045).
Survival
Thirteen controls and 8 enoxaparin-treated patients died (P ϭ .251). Causes of death were sepsis (4 enoxaparin, 6 controls), progressive liver failure (5 controls), hepatocellular carcinoma (2 enoxaparin, 1 control), esophageal variceal bleeding (1 in each group), and hemoperitoneum from intra-abdominal hepatocellular carcinoma rupture (1 enoxaparin). Kaplan-Meier curve analysis revealed a higher survival rate in the enoxaparintreated group than in controls ( Figure 1C ) (P ϭ .020). Independent factors related to survival were enoxaparin treatment (HR, 0.366; 95% CI, 0.082-0.795; P ϭ .018) and portal vein diameter (HR, 1.349; 95% CI, 1.051-1.731; P ϭ .019) (Supplementary Table 3 ). 
CLINICAL LIVER
Rate of Bacterial Infections and Biomarkers of Microbial Translocation
A significantly different rate of bacterial infections (either as SBP or bacteremia) occurred during the year of active treatment between enoxaparin-treated patients and controls (3 of 34 [8.8%] and 12 of 36 [33.3%], respectively; P ϭ .019). Therapy with intravenous antibiotics was strictly related to occurrence of bacterial infections and was therefore less used in enoxaparin-treated patients. Use of poorly absorbed antibiotics was not significantly different between cases and controls.
To explore a possible counteracting effect of enoxaparin on bacterial translocation as a factor determining the observed prevention of PVT and decompensation in our cohort of cirrhotic patients, we evaluated circulating biomarkers of intestinal integrity and immune activation to bacterial products.
Paired levels of I-FABP showed no difference at weeks 0, 48, or 72 in controls. In enoxaparin-treated subjects, paired levels of I-FABP were decreased at week 48 (P ϭ .003) ( Figure 3A) . Baseline I-FABP levels correlated with greater portal vein diameter (r ϭ 0.638, P ϭ .006). In controls, paired levels of IL-6 showed no difference at weeks 0 and 48, but levels at week 72 were higher than at baseline (P ϭ .046). During enoxaparin treatment, levels at week 48 were decreased compared with baseline (P ϭ .012) ( Figure 3B ). Higher baseline IL-6 level positively correlated with baseline CD14 levels (r ϭ 0.525, P ϭ .006) and survival (nonsurvivors, 8.7 Ϯ 5.5 pg/mL vs survivors, 5.3 Ϯ 4.1 pg/mL; P ϭ .022).
To identify the presence of bacterial DNA, 16S rDNA was amplified from patient sera at baseline (0 weeks; n ϭ 68 samples), 48 weeks (end of the active treatment period; n ϭ 60), and 72 weeks (end of follow-up period; n ϭ 55). At baseline, all but 4 serum samples (2 per group) were positive for bacterial DNA. All but 2 controls gave consistently positive results at 48 and 72 weeks. At 48 weeks, 64.5% of serum samples from surviving enoxaparin-treated patients (21 of 32) were negative for bacterial DNA (P Ͻ .0001); they reverted to positive at week 72 ( Figure 3C ).
To evaluate host response to microbial products, we measured basal levels of serum CD14. Baseline and follow-up levels did not differ significantly in controls, whereas enoxaparin treatment was associated with a decrease in sCD14 levels at week 48 (P ϭ .004) ( Figure 3D ). Baseline sCD14 was associated with occurrence of PVT (r ϭ 0.417, P ϭ .030).
Safety
Enoxaparin treatment was very well tolerated. Only 1 patient stopped treatment at week 36 for marked Figure 3 . Baseline levels of markers of (A) enterocyte death, (B) inflammatory reaction, (C) microbial translocation, and (D) host response to microbial products were increased in both groups. All 4 biomarkers were decreased significantly at week 48 (end of treatment) in the enoxaparin group but not in controls. IL-6 levels steadily increased in controls throughout the observation period. Bars, standard deviation; horizontal lines, median value and 5%-95% range. P values were calculated with the Mann-Whitney U test.
thrombocytopenia. On the whole, platelet count significantly decreased in enoxaparin-treated patients during treatment (baseline vs week 48: 100 Ϯ 42 ϫ 10 3 /mm 3 vs 56 Ϯ 78 ϫ 10 3 /mm 3 ϫ 10 3 /mm 3 , P ϭ .002, paired t test) to return to baseline after stopping the drug (baseline vs week 96: 97 Ϯ 38 ϫ 10 3 /mm 3 vs 103 Ϯ 63 ϫ 10 3 /mm 3 ϫ 10 3 /mm 3 , P ϭ .850, paired t test). No difference was observed in controls.
There were 3 bleeding episodes from ruptured esophageal varices, 2 in treated patients and 1 in the control group (P ϭ .521). They were controlled by conservative endoscopic therapy. Three episodes of epistaxis (1 in the control group, 2 in the enoxaparin-treated group) were also encountered. No significant difference from baseline was observed in hemoglobin levels during the year of active treatment and during the follow-up period in each of the groups.
Discussion
The results of this RCT in a cohort of patients with advanced cirrhosis showed that anticoagulant treatment with enoxaparin is safe and effective, significantly reducing risk of PVT development and liver decompensation, markedly improving liver function and Child-Pugh score, and increasing overall survival. Our findings are consistent with data showing that successful PVT recanalization is accompanied by improvement of the Child-Pugh score. 23 It is plausible that PVT prevention has a protective role in liver disease progression. Nevertheless, taken alone, PVT prevention by enoxaparin cannot explain the observed improvement in terms of liver decompensation and survival. Enoxaparin treatment was associated with a definite improvement of liver function and a striking decrease of occurrence or recurrence of decompensation (mostly ascites), a favorable effect that was much greater than the mere prevention of PVT. Although PVT prevention may be attributed to the anticoagulant action of enoxaparin, its effect on decompensation is less obvious. Although this study was not designed to clarify the pathogenetic link between enoxaparin treatment and the prevention of PVT or improvement of the course of liver disease, some hypotheses can be made.
PH has severe consequences for the upper and lower gastrointestinal tracts. 24 In the colon, PH is associated with profound changes in the intestinal microcirculation, leading to microthrombosis. 25 It can lead to ischemic damage of enterocytes, followed by a marked increase in permeability of the intestinal mucosa, a key factor for bacterial translocation, 26 progression of liver damage, 20 and decompensation. 27 Our patients displayed extremely high I-FABP serum levels that correlated positively on ultrasound with the portal vein diameter (a well-known surrogate for PH). The protein I-FABP is made exclusively by enterocytes, and it is released into the circulation upon enterocyte necrosis. A high percentage of subjects were positive for circulating 16S rDNA. Patients also displayed extremely high baseline levels of CD14, a marker of immune activation against lipopolysaccharide, 20 and showed markedly increased levels of IL-6, a biomarker of inflammation associated with endotoxemia and sepsis. 28 Therefore, the protective effect of enoxaparin on the course of liver disease might be mediated by an improvement of intestinal microcirculation able to improve enterocytic damage and therefore reducing bacterial translocation. In this view, enoxaparin could act on microthrombosis, facilitating blood flow and improving endothelial function by interfering with the hypercoagulable state through tissue factor, a molecule that plays an extremely relevant role 29 in initiating septic coagulopathy after activation by bacterial endotoxins, lipopolysaccharide, and Toll-like receptor 4. 30 As might be expected, the positive effect was bound to drug administration and maintained only for some time after its discontinuation; this suggests the opportunity of performing larger double-blind RCTs encompassing longer treatment periods and evaluating, at the same time, modifications of portal hypertension through protocolized endoscopies and hepatic venous pressure gradient measurement.
Taken together, our data suggest that cirrhotic patients are at increased risk for thrombotic events, particularly in the portal venous system. In our view, PVT and decompensation are similar expressions of a rapidly worsening PH. By damaging the intestinal mucosal barrier, severe PH leads to systemic dissemination of enteric-borne infection, inappropriate activation of the coagulation system (which is delicately balanced in the cirrhotic patient), 31 and strong up-regulation of systemic inflammation.
The main limitation of this study was in the relatively low number of patients enrolled. A further methodologic question is the potentially limited external validity of the results for different populations and settings. Our study included a cohort of Italian patients enrolled at a tertiary care center, with advanced cirrhosis arising from different etiologies. Lastly, we did not test for anti-Xa activity: this is a relevant issue that should be addressed in future trials together with evaluation of novel tests that work independently of antithrombin III concentrations. 32 In conclusion, we showed that enoxaparin treatment is safe in patients with advanced cirrhosis, as it has been shown in the treatment of established PVT. 17 No potentially life-threatening side effects occurred, and the occurrence of bleeding episodes did not differ between the control (1 episode) and enoxaparin groups (2 episodes) (P ϭ .521). Future therapeutic interventions should aim to reinforce prevention of the microvascular disturbances associated with PVT progression, acting well before establishment of end-stage liver disease. 24 
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